This invention relates to novel diazabicyclic aryl compounds of the
formula ##STR00001## wherein: R' represents hydrogen or alkyl; A
represents an aromatic monocyclic or bicyclic carbocyclic or
heterocyclic; and is hydrogen or a subsituent as defined in the
specification. The compounds are cholinergic ligands at the nicotinic
acetylcholine receptors and modulators of the monoamine receptors and
transporters. The compounds of the invention may be useful for the
treatment of diseases or disorders as diverse as those related to the
cholinergic system of the central nervous system (CNS), the peripheral
nervous system (PNS), diseases or disorders related to smooth muscle
contraction, endocrine diseases or disorders, diseases or disorders
related to neuro-degeneration, diseases or disorders related to
inflammation, pain, and withdrawal symptoms caused by the termination of
abuse of chemical substances.